Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Noventa

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Reviews on Recent Clinical Trials|August 1, 2019
Yoga Protocol for Cancer Patients: A Systematic Exploration of Psychophysiological BenefitsMara Mirandola, Miguel David Sabogal Rueda, Federica Andreis, et al.
Reviews on Recent Clinical Trials|April 10, 2018
Impact of a Psycho-Educational Team in early Breast Cancer Patients' Coping Strategies: The Venere ProjectFederica Andreis, Fausto Meriggi, Claudio Codignola, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2024
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancerTiziana Pressiani, Rita Balsano, Laura Giordano, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genesAnna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
Cancer Medicine|June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinomaLetizia Procaccio, Valeria Merz, Morena Fasano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Oncology|August 22, 2018
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramFilippo Pietrantonio, Francesco Barretta, Valentina Fanotto, et al.
Cancer Medicine|June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatmentGuido Giordano, Michele Milella, Matteo Landriscina, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Reviews on Recent Clinical Trials|August 1, 2019
Yoga Protocol for Cancer Patients: A Systematic Exploration of Psychophysiological BenefitsMara Mirandola, Miguel David Sabogal Rueda, Federica Andreis, et al.
Reviews on Recent Clinical Trials|April 10, 2018
Impact of a Psycho-Educational Team in early Breast Cancer Patients' Coping Strategies: The Venere ProjectFederica Andreis, Fausto Meriggi, Claudio Codignola, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2024
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancerTiziana Pressiani, Rita Balsano, Laura Giordano, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genesAnna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
Cancer Medicine|June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinomaLetizia Procaccio, Valeria Merz, Morena Fasano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Oncology|August 22, 2018
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramFilippo Pietrantonio, Francesco Barretta, Valentina Fanotto, et al.
Cancer Medicine|June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatmentGuido Giordano, Michele Milella, Matteo Landriscina, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
Pageof 3